Blackstone Inc
CRNX icon

Blackstone Inc’s Crinetics Pharmaceuticals CRNX Stock Holding History

Blackstone Inc’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,334
Closed -$512K – 543
2021
Q3 		$512K Buy
+24,334
New +$509K ﹤0.01% 404

Other funds holding CRNX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Blackstone Inc's CRNX Position: Q4 2021 in Review

Blackstone Inc sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2021, closing a stake of 24,334 shares — an estimated $512K sold.

Blackstone Inc first reported a position in CRNX in Q3 2021 and held it in 1 quarter. The position peaked at $512K in Q3 2021. 118 funds tracked by Wall St. Rank hold CRNX as of Q4 2021.

  • Blackstone Inc reported no remaining Crinetics Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Blackstone Inc sold 24,334 Crinetics Pharmaceuticals shares in Q4 2021, an estimated $512K.
  • Blackstone Inc first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Blackstone Inc's Crinetics Pharmaceuticals position peaked at $512K in Q3 2021.
  • 118 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2021.

Based on Blackstone Inc's 13F filing for Q4 2021, filed 14 Feb 2022.